Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630

Key clinical point: The 11-week high intensity interval training (HIIT) regimen had no influence on the bone marrow edema (BME) in patients with psoriatic arthritis (PsA).

Major finding: After 11 weeks, similar proportions of patients in the HIIT and control (no changes in exercise regimen) groups had BME changes, as assessed by a radiologist (P  =  .5) and SpondyloArthritis Research Consortium of Canada scores (P  =  1). Although the values of 20 textural features were significantly different in the voxels of BME vs healthy bone marrow (P < .001), the textural features of PsA lesions were similar between the HIIT and control groups (P > .2).

Study details: Findings are from the analysis of a part of a randomized controlled trial including 37 patients with PsA who performed HIIT 3 times/week for 11 weeks or followed the control regimen and were evaluated by MRI.

Disclosures: This research was funded by Norwegian Extra Foundation for Health and Rehabilitation and Sør-Trøndelag University college. The authors declared no conflicts of interest.

Source: Chronaiou I et al. Evaluating the impact of high intensity interval training on axial psoriatic arthritis based on MR images. Diagnostics (Basel). 2022;12(6):1420 (Jun 8). Doi: 10.3390/diagnostics12061420

Key clinical point: The 11-week high intensity interval training (HIIT) regimen had no influence on the bone marrow edema (BME) in patients with psoriatic arthritis (PsA).

Major finding: After 11 weeks, similar proportions of patients in the HIIT and control (no changes in exercise regimen) groups had BME changes, as assessed by a radiologist (P  =  .5) and SpondyloArthritis Research Consortium of Canada scores (P  =  1). Although the values of 20 textural features were significantly different in the voxels of BME vs healthy bone marrow (P < .001), the textural features of PsA lesions were similar between the HIIT and control groups (P > .2).

Study details: Findings are from the analysis of a part of a randomized controlled trial including 37 patients with PsA who performed HIIT 3 times/week for 11 weeks or followed the control regimen and were evaluated by MRI.

Disclosures: This research was funded by Norwegian Extra Foundation for Health and Rehabilitation and Sør-Trøndelag University college. The authors declared no conflicts of interest.

Source: Chronaiou I et al. Evaluating the impact of high intensity interval training on axial psoriatic arthritis based on MR images. Diagnostics (Basel). 2022;12(6):1420 (Jun 8). Doi: 10.3390/diagnostics12061420

Key clinical point: The 11-week high intensity interval training (HIIT) regimen had no influence on the bone marrow edema (BME) in patients with psoriatic arthritis (PsA).

Major finding: After 11 weeks, similar proportions of patients in the HIIT and control (no changes in exercise regimen) groups had BME changes, as assessed by a radiologist (P  =  .5) and SpondyloArthritis Research Consortium of Canada scores (P  =  1). Although the values of 20 textural features were significantly different in the voxels of BME vs healthy bone marrow (P < .001), the textural features of PsA lesions were similar between the HIIT and control groups (P > .2).

Study details: Findings are from the analysis of a part of a randomized controlled trial including 37 patients with PsA who performed HIIT 3 times/week for 11 weeks or followed the control regimen and were evaluated by MRI.

Disclosures: This research was funded by Norwegian Extra Foundation for Health and Rehabilitation and Sør-Trøndelag University college. The authors declared no conflicts of interest.

Source: Chronaiou I et al. Evaluating the impact of high intensity interval training on axial psoriatic arthritis based on MR images. Diagnostics (Basel). 2022;12(6):1420 (Jun 8). Doi: 10.3390/diagnostics12061420

Key clinical point: Patients with concomitant psoriasis and psoriatic arthritis (PsA) vs only psoriasis were more likely to experience mild depressive symptoms and anxiety, with the association being mediated by pain.

Major finding: Among patients with psoriasis, those with vs without PsA had a higher prevalence of mild depressive symptoms (Hospital Anxiety and Depression Scale [HADS] score ≥8: adjusted odds ratio [aOR] 1.64; P  =  .037) but not severe depressive symptoms (HADS score ≥ 11) and a high prevalence of mild-to-severe anxiety (HADS score ≥ 8: aOR 1.51; P  =  .038 and HADS score ≥ 11; aOR 1.62; P  =  .037). Pain mediated the effect of PsA on depression and anxiety.

Study details: The data of 707 British Association of Dermatologists Biologic and Immunomodulators Register participants (540 with psoriasis and 167 with both psoriasis and PsA) were analyzed.

Disclosures: This study was funded by the UK National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Some authors declared serving as speakers or advisory board members, or receiving honoraria, funding, compensation, research grants, or consulting fees from several sources.

Source: Lada G et al. Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health Dis. 2022;e149 (Jul 6). Doi: 10.1002/ski2.149

Key clinical point: Patients with concomitant psoriasis and psoriatic arthritis (PsA) vs only psoriasis were more likely to experience mild depressive symptoms and anxiety, with the association being mediated by pain.

Major finding: Among patients with psoriasis, those with vs without PsA had a higher prevalence of mild depressive symptoms (Hospital Anxiety and Depression Scale [HADS] score ≥8: adjusted odds ratio [aOR] 1.64; P  =  .037) but not severe depressive symptoms (HADS score ≥ 11) and a high prevalence of mild-to-severe anxiety (HADS score ≥ 8: aOR 1.51; P  =  .038 and HADS score ≥ 11; aOR 1.62; P  =  .037). Pain mediated the effect of PsA on depression and anxiety.

Study details: The data of 707 British Association of Dermatologists Biologic and Immunomodulators Register participants (540 with psoriasis and 167 with both psoriasis and PsA) were analyzed.

Disclosures: This study was funded by the UK National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Some authors declared serving as speakers or advisory board members, or receiving honoraria, funding, compensation, research grants, or consulting fees from several sources.

Source: Lada G et al. Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health Dis. 2022;e149 (Jul 6). Doi: 10.1002/ski2.149

Key clinical point: Patients with concomitant psoriasis and psoriatic arthritis (PsA) vs only psoriasis were more likely to experience mild depressive symptoms and anxiety, with the association being mediated by pain.

Major finding: Among patients with psoriasis, those with vs without PsA had a higher prevalence of mild depressive symptoms (Hospital Anxiety and Depression Scale [HADS] score ≥8: adjusted odds ratio [aOR] 1.64; P  =  .037) but not severe depressive symptoms (HADS score ≥ 11) and a high prevalence of mild-to-severe anxiety (HADS score ≥ 8: aOR 1.51; P  =  .038 and HADS score ≥ 11; aOR 1.62; P  =  .037). Pain mediated the effect of PsA on depression and anxiety.

Study details: The data of 707 British Association of Dermatologists Biologic and Immunomodulators Register participants (540 with psoriasis and 167 with both psoriasis and PsA) were analyzed.

Disclosures: This study was funded by the UK National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Some authors declared serving as speakers or advisory board members, or receiving honoraria, funding, compensation, research grants, or consulting fees from several sources.

Source: Lada G et al. Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health Dis. 2022;e149 (Jul 6). Doi: 10.1002/ski2.149

Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).

Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P  =  .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P  =  .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.

Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).

Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.

Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3

Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).

Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P  =  .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P  =  .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.

Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).

Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.

Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3

Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).

Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P  =  .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P  =  .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.

Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).

Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.

Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3

Key clinical point: Systemic-therapy-naive patients with psoriatic arthritis (PsA) treated with apremilast required a longer time and were less likely to initiate biologic therapy than those treated with methotrexate in the real world.

Major finding: Patients receiving apremilast vs methotrexate had a significantly longer mean time to biologic initiation (194.1 vs 138.7 days; P < .001) and were 58% less likely to use any biologics at 1-year follow-up (odds ratio [OR] 0.42; P < .001), with the likelihood of biologic use being consistently low at 2-year follow-up (OR 0.46; P < .001).

Study details: Findings are from a retrospective, observational, cohort study including 2116 systemic-therapy-naive patients with PsA who initiated apremilast (n = 534) or methotrexate (n = 1582) before initiating biologics.

Disclosures: This study was funded by Amgen Inc. Eight authors reported owning stocks or being current or former employees of Amgen or a company contracted by Amgen.

Source: Husni ME et al. biologic initiation rate in systemic-naïve psoriatic arthritis patients starting treatment with apremilast vs methotrexate: 1-year retrospective analysis of a US claims database. Open Access Rheumatol. 2022;14:123-132 (Jun 15). Doi: 10.2147/OARRR.S342123

Key clinical point: Systemic-therapy-naive patients with psoriatic arthritis (PsA) treated with apremilast required a longer time and were less likely to initiate biologic therapy than those treated with methotrexate in the real world.

Major finding: Patients receiving apremilast vs methotrexate had a significantly longer mean time to biologic initiation (194.1 vs 138.7 days; P < .001) and were 58% less likely to use any biologics at 1-year follow-up (odds ratio [OR] 0.42; P < .001), with the likelihood of biologic use being consistently low at 2-year follow-up (OR 0.46; P < .001).

Study details: Findings are from a retrospective, observational, cohort study including 2116 systemic-therapy-naive patients with PsA who initiated apremilast (n = 534) or methotrexate (n = 1582) before initiating biologics.

Disclosures: This study was funded by Amgen Inc. Eight authors reported owning stocks or being current or former employees of Amgen or a company contracted by Amgen.

Source: Husni ME et al. biologic initiation rate in systemic-naïve psoriatic arthritis patients starting treatment with apremilast vs methotrexate: 1-year retrospective analysis of a US claims database. Open Access Rheumatol. 2022;14:123-132 (Jun 15). Doi: 10.2147/OARRR.S342123

Key clinical point: Systemic-therapy-naive patients with psoriatic arthritis (PsA) treated with apremilast required a longer time and were less likely to initiate biologic therapy than those treated with methotrexate in the real world.

Major finding: Patients receiving apremilast vs methotrexate had a significantly longer mean time to biologic initiation (194.1 vs 138.7 days; P < .001) and were 58% less likely to use any biologics at 1-year follow-up (odds ratio [OR] 0.42; P < .001), with the likelihood of biologic use being consistently low at 2-year follow-up (OR 0.46; P < .001).

Study details: Findings are from a retrospective, observational, cohort study including 2116 systemic-therapy-naive patients with PsA who initiated apremilast (n = 534) or methotrexate (n = 1582) before initiating biologics.

Disclosures: This study was funded by Amgen Inc. Eight authors reported owning stocks or being current or former employees of Amgen or a company contracted by Amgen.

Source: Husni ME et al. biologic initiation rate in systemic-naïve psoriatic arthritis patients starting treatment with apremilast vs methotrexate: 1-year retrospective analysis of a US claims database. Open Access Rheumatol. 2022;14:123-132 (Jun 15). Doi: 10.2147/OARRR.S342123

Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).

Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.

Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.

Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.

Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x

Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).

Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.

Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.

Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.

Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x

Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).

Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.

Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.

Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.

Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x

Key clinical point: Patients with psoriatic arthritis (PsA) who received 100 mg guselkumab once every 4 or 8 weeks (Q4W/Q8W) achieved clinically meaningful improvements through 1 year in several domains of the Patient-Reported Outcomes Measurement Information System.

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W/Q8W achieved ≥ 5-point improvement in fatigue and sleep disturbance (both P < .05) and in pain interference, physical function, social participation, and pain intensity (all P < .001) compared to patients receiving a placebo. A ≥ 5-point improvement in anxiety (P < .05) and depression (P < .01) was achieved by more patients receiving guselkumab Q8W compared to placebo. The improvements were maintained till week 52.

Study details: The findings are from the phase 3 DISCOVER 1 study including 381 patients with active PsA and an inadequate response or tolerance to standard treatments. The patients were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was funded by Janssen Research & Development, LLC. Seven authors declared being employees of Janssen and stockholders of Johnson and Johnson, the parent company of Janssen. The other authors reported ties with several sources, including Janssen.

Source: Orbai AM et al. Meaningful improvement in general health outcomes with guselkumab treatment for psoriatic arthritis: Patient-reported outcomes measurement information system-29 results from a phase 3 study. Patient. 2022 (Jun 30). Doi: 10.1007/s40271-022-00588-6

Key clinical point: Patients with psoriatic arthritis (PsA) who received 100 mg guselkumab once every 4 or 8 weeks (Q4W/Q8W) achieved clinically meaningful improvements through 1 year in several domains of the Patient-Reported Outcomes Measurement Information System.

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W/Q8W achieved ≥ 5-point improvement in fatigue and sleep disturbance (both P < .05) and in pain interference, physical function, social participation, and pain intensity (all P < .001) compared to patients receiving a placebo. A ≥ 5-point improvement in anxiety (P < .05) and depression (P < .01) was achieved by more patients receiving guselkumab Q8W compared to placebo. The improvements were maintained till week 52.

Study details: The findings are from the phase 3 DISCOVER 1 study including 381 patients with active PsA and an inadequate response or tolerance to standard treatments. The patients were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was funded by Janssen Research & Development, LLC. Seven authors declared being employees of Janssen and stockholders of Johnson and Johnson, the parent company of Janssen. The other authors reported ties with several sources, including Janssen.

Source: Orbai AM et al. Meaningful improvement in general health outcomes with guselkumab treatment for psoriatic arthritis: Patient-reported outcomes measurement information system-29 results from a phase 3 study. Patient. 2022 (Jun 30). Doi: 10.1007/s40271-022-00588-6

Key clinical point: Patients with psoriatic arthritis (PsA) who received 100 mg guselkumab once every 4 or 8 weeks (Q4W/Q8W) achieved clinically meaningful improvements through 1 year in several domains of the Patient-Reported Outcomes Measurement Information System.

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W/Q8W achieved ≥ 5-point improvement in fatigue and sleep disturbance (both P < .05) and in pain interference, physical function, social participation, and pain intensity (all P < .001) compared to patients receiving a placebo. A ≥ 5-point improvement in anxiety (P < .05) and depression (P < .01) was achieved by more patients receiving guselkumab Q8W compared to placebo. The improvements were maintained till week 52.

Study details: The findings are from the phase 3 DISCOVER 1 study including 381 patients with active PsA and an inadequate response or tolerance to standard treatments. The patients were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.

Disclosures: This study was funded by Janssen Research & Development, LLC. Seven authors declared being employees of Janssen and stockholders of Johnson and Johnson, the parent company of Janssen. The other authors reported ties with several sources, including Janssen.

Source: Orbai AM et al. Meaningful improvement in general health outcomes with guselkumab treatment for psoriatic arthritis: Patient-reported outcomes measurement information system-29 results from a phase 3 study. Patient. 2022 (Jun 30). Doi: 10.1007/s40271-022-00588-6

Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.

Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.

Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286

Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.

Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.

Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286

Key clinical point: Risankizumab led to a significant improvement in patient-reported outcomes compared with placebo in patients with psoriatic arthritis (PsA) and an inadequate response to 1 or 2 biologics (Bio-IR) or ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: At week 24, patients receiving risankizumab reported a significantly greater improvement in the mean pain index (−14.7 vs −6.5; P < .001), fatigue score (4.9 vs 2.6; P < .01), patient’s global assessment of disease activity (−16.5 vs −7.7; P < .001), general health status (0.09 vs 0.01; P < .001), and physical functioning (5.1 vs 2.0; P < .001), compared to placebo.

Study details: Findings are from the phase 3 KEEPsAKE2 study including 443 patients with active PsA and Bio-IR or csDMARD-IR who were randomly assigned to receive 150 mg risankizumab or placebo.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or stockholders at AbbVie, and other authors reported ties with several sources, including AbbVie.

Source: Ostor AJK et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: Analysis of the Phase 3 trial KEEPsAKE 2. RMD Open. 2022;8:e002286 (Jun 14). Doi: 10.1136/rmdopen-2022-002286